James C. Dickerson

Oncology

300 Pasteur Dr
Palo Alto, CA 94304

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Evolving Landscape of Immunotherapy in Melanoma.

Evolving Landscape of Immunotherapy in Melanoma.

Journal: JCO oncology practice

Published: June 25, 2026

Fully Automated Abstraction of Longitudinal Breast Oncology Records with Off-The-Shelf Large Language Models.

Fully Automated Abstraction of Longitudinal Breast Oncology Records with Off-The-Shelf Large Language Models.

Journal: medRxiv : the preprint server for health sciences

Published: April 03, 2026

Guideline concordance in triple-negative breast cancer: What does it measure?

Guideline concordance in triple-negative breast cancer: What does it measure?

Journal: Cancer

Published: March 29, 2026

Decluttering chemotherapy agents for HER2+early breast cancer: Do we still need carboplatin?

Decluttering chemotherapy agents for HER2+early breast cancer: Do we still need carboplatin?

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 20, 2026

Improving human papillomavirus vaccine uptake in low- and middle-income countries: a narrative review of implementation and education strategies.

Improving human papillomavirus vaccine uptake in low- and middle-income countries: a narrative review of implementation and education strategies.

Journal: BMC global and public health

Published: November 18, 2025

Reply to: Comment on Human Epidermal Growth Factor Receptor 2-Low Metastatic Breast Cancer Treatment Costs and Cost-Effectiveness.

Reply to: Comment on Human Epidermal Growth Factor Receptor 2-Low Metastatic Breast Cancer Treatment Costs and Cost-Effectiveness.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 24, 2025

Why Adjuvant Treatment With a CDK4/6 Inhibitor Should Be Recommended for Women With High-Risk Breast Cancer: Methodologic Considerations on Available Evidence.

Why Adjuvant Treatment With a CDK4/6 Inhibitor Should Be Recommended for Women With High-Risk Breast Cancer: Methodologic Considerations on Available Evidence.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 17, 2025

Susan G. Komen's ShareForCures®: a patient-engaged, nationwide breast cancer research registry.

Susan G. Komen's ShareForCures®: a patient-engaged, nationwide breast cancer research registry.

Journal: Journal of the National Cancer Institute

Published: September 01, 2025

Physician Specialization and Receipt of Updated Breast Cancer Care in the United States: A SEER-Medicare Analysis.

Physician Specialization and Receipt of Updated Breast Cancer Care in the United States: A SEER-Medicare Analysis.

Journal: JCO oncology practice

Published: July 02, 2025

Cost and Cost-Effectiveness of Treating Human Epidermal Growth Factor Receptor 2-Low Metastatic Breast Cancer.

Cost and Cost-Effectiveness of Treating Human Epidermal Growth Factor Receptor 2-Low Metastatic Breast Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 21, 2025

Endocrine Therapy Interruption, Resumption, and Outcomes Associated With Pregnancy After Breast Cancer.

Endocrine Therapy Interruption, Resumption, and Outcomes Associated With Pregnancy After Breast Cancer.

Journal: JAMA oncology

Published: February 13, 2025

Inpatient Immunotherapy Outcomes Study: A Multicenter Retrospective Analysis.

Inpatient Immunotherapy Outcomes Study: A Multicenter Retrospective Analysis.

Journal: JCO oncology practice

Published: February 12, 2025

Showing 1-12 of 22

Last Updated: 09/26/2026